$1.90
+0.01(0.80%)
Mkt Cap $314M
$0.54
$2.50
52-Week Range
At a Glance
AI-generatedPalisade Bio, Inc., a clinical-stage biopharmaceutical company, reported a net loss of $16.8 million for FY 2025, ending December 31, 2025, compared to $14.4 million in FY 2024, driven by increased operating expenses of $18.1 million versus $14.9 million prior year.
8-K
Palisade Bio, Inc. entered into a master services agreement with Iterative Health to support patient enrollment for its upcoming Phase 2 study of PALI-2108 in moderate-to-severe ulcerative colitis and concurrently sold 1,536,885 shares of common stock to an Iterative Health affiliate for $3.0 million in an unregistered offering.$314M
Market Cap
—
Revenue
-$45M
Net Income
Employees8
Fundamentals
How The Business Makes Money
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.
Industry Biotechnology
Activity
Analyst View
Company Profile
CIK0001357459
ISINUS6963894026
CUSIP696389105
Phone858 704 4900
Address5800 Armada Drive, Carlsbad, CA, 92008, US
SEC EDGAR